GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shanghai Kaibao Pharmaceutical Co 300039.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

4.84

+1.04%

Close of 10 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥1.15bn

FY2016FY2025

Net income

CN¥278.6m

FY2016FY2025

Free cash flow

CN¥203.7m

FY2016FY2025

Shareholders' equity

CN¥4.42bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥1.15bnCN¥1.47bnCN¥1.59bnCN¥1.12bnCN¥1.10bnCN¥908.0mCN¥1.42bnCN¥1.50bnCN¥1.57bnCN¥1.50bn
Gross profitCN¥930.6mCN¥1.20bnCN¥1.28bnCN¥871.0mCN¥866.5mCN¥727.5mCN¥1.17bnCN¥1.24bnCN¥1.28bnCN¥1.22bn
Research and developmentCN¥88.3mCN¥99.8mCN¥95.9mCN¥53.0mCN¥79.3mCN¥59.1mCN¥54.6mCN¥47.5mCN¥64.7mCN¥53.4m
Operating incomeCN¥272.4mCN¥438.2mCN¥383.0mCN¥228.4mCN¥171.8mCN¥134.4mCN¥301.8mCN¥274.9mCN¥332.6mCN¥325.0m
Net incomeCN¥278.6mCN¥375.6mCN¥327.9mCN¥190.8mCN¥140.1mCN¥106.1mCN¥251.0mCN¥226.8mCN¥272.3mCN¥282.6m
Diluted earnings per share0.270.360.310.180.130.100.230.220.240.27

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥4.78bnCN¥4.52bnCN¥4.58bnCN¥4.26bnCN¥3.36bnCN¥2.88bnCN¥2.84bnCN¥2.75bnCN¥2.68bnCN¥2.53bn
Cash and short-term investments—CN¥773.3mCN¥752.0mCN¥830.8mCN¥1.40bnCN¥1.42bnCN¥1.30bnCN¥631.3mCN¥685.4mCN¥743.2m
Total liabilitiesCN¥359.6mCN¥415.4mCN¥546.8mCN¥498.2mCN¥310.9mCN¥299.0mCN¥273.0mCN¥262.3mCN¥314.3mCN¥327.6m
Debt—CN¥5.4mCN¥4.3mCN¥9.1mCN¥7.7mCN¥35.7m—CN¥95,000CN¥16.0mCN¥28.8m
Shareholders' equityCN¥4.42bnCN¥4.10bnCN¥4.03bnCN¥3.76bnCN¥3.04bnCN¥2.58bnCN¥2.57bnCN¥2.49bnCN¥2.37bnCN¥2.20bn
Shares outstanding1,046m1,045m1,045m1,046m1,045m1,045m1,099m1,043m1,143m1,052m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥230.7mCN¥279.0mCN¥382.7mCN¥376.4mCN¥126.1mCN¥250.6mCN¥334.1mCN¥262.4mCN¥245.8mCN¥314.9m
Capital spending−CN¥27.0m−CN¥140.5m−CN¥29.1m−CN¥31.6m−CN¥42.5m−CN¥13.9m−CN¥15.5m−CN¥26.1m−CN¥49.2m−CN¥27.0m
Free cash flowCN¥203.7mCN¥138.4mCN¥353.6mCN¥344.8mCN¥83.5mCN¥236.7mCN¥318.6mCN¥236.3mCN¥196.5mCN¥287.8m
Dividends paid−CN¥136.0m−CN¥104.6m−CN¥62.8m−CN¥52.3m−CN¥31.4m−CN¥104.6m−CN¥106.4m−CN¥107.1m−CN¥107.1m−CN¥82.4m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥179.7mCN¥283.3mCN¥333.6mCN¥214.4mCN¥204.0mCN¥400.6mCN¥352.1mCN¥292.1m
Gross profitCN¥142.2mCN¥228.9mCN¥269.3mCN¥170.7mCN¥162.3mCN¥328.3mCN¥288.8mCN¥235.2m
Operating incomeCN¥33.4mCN¥68.0mCN¥97.9mCN¥75.9mCN¥41.6mCN¥103.3mCN¥181.6mCN¥87.4m
Net incomeCN¥37.1mCN¥64.9mCN¥91.5mCN¥65.1mCN¥37.7mCN¥84.3mCN¥158.5mCN¥74.9m
Diluted earnings per share0.040.060.090.060.040.080.150.07
Cash from operations———CN¥190.0mCN¥71.0mCN¥88.0m—CN¥130.0m
Capital spending−CN¥2.0m−CN¥1.0m−CN¥9.0m−CN¥3.0m−CN¥8.0m−CN¥5.0m−CN¥2.0m—
Free cash flow———CN¥187.0mCN¥63.0mCN¥83.0m——
Total assetsCN¥4.59bnCN¥5.09bnCN¥4.78bnCN¥4.96bnCN¥4.67bnCN¥4.68bnCN¥4.52bnCN¥4.33bn
Cash and short-term investments———CN¥1.64bnCN¥799.7mCN¥879.1mCN¥773.3mCN¥1.32bn
Debt———CN¥4.2mCN¥5.6mCN¥6.2mCN¥5.4mCN¥3.0m
Shareholders' equityCN¥4.28bnCN¥4.68bnCN¥4.42bnCN¥4.54bnCN¥4.26bnCN¥4.21bnCN¥4.10bnCN¥3.85bn

Financial ratios

Data as of 12 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2017FY2014FY2009FY2008
Gross margin80.7%81.5%80.4%77.8%78.7%80.1%————
Operating margin27.9%29.5%24.1%20.2%15.4%14.6%————
Net margin24.2%25.5%20.6%17.1%12.7%11.7%————
Return on equity6.3%9.2%8.1%5.1%4.6%4.1%————
Return on assets5.8%8.3%7.2%4.5%4.2%3.7%————
Free cash flow yield4.7%7.7%7.5%7.5%3.1%4.8%————
Revenue growth-21.8%-7.6%42.5%1.7%21.2%-36.0%————
Earnings growth-25.8%14.6%71.8%36.2%32.0%-57.7%————
Current ratio13.41x10.40x4.40x5.32x11.82x9.34x————
Debt to equity—0.00x———0.01x0.01x0.02x0.10x0.15x
Equity ratio92.5%90.8%88.0%88.3%90.7%89.6%————
Interest coverage3262.86x2907.95x3236.20x1777.58x1143.44x171.60x————
R&D as a share of sales7.7%6.8%6.0%4.7%7.2%6.5%————
Buybacks as a share of market value-0.1%0.0%0.1%-0.1%-0.1%5.0%————

Growth per year

Compound annual rate

3 years5 years10 years
Revenue1.0%4.9%-1.9%
Operating income6.1%15.2%-1.8%
Net income13.4%21.3%-0.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin81.1%80.2%80.0%80.9%
Operating margin27.1%24.8%22.2%21.7%
Net margin24.9%22.0%19.3%18.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings22.717.221.244.246.047.921.918.726.729.3
Price to sales5.54.44.47.55.85.63.92.84.65.5

Dividends and splits

Per share, in the currency the company pays

Paid for 16 years. Last went ex-dividend on 27 Nov 2025.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year0.130.100.060.050.030.100.100.10
  • 13-for-10 split · 10 May 2017
  • 13-for-10 split · 30 Apr 2015
  • 6-for-5 split · 2 Apr 2014
  • 2-for-1 split · 2 Apr 2013
  • 3-for-2 split · 29 Apr 2011
  • 8-for-5 split · 26 Apr 2010

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.